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Abstract
Objective: The combined thickness of the intima and media of the carotid artery (carotid intima-medial thickness, CIMT) is
associated with cardiovascular disease and stroke. Previous studies indicate that carotid intima-medial thickness is a
significantly heritable phenotype, but the responsible genes are largely unknown. Hexose-6 phosphate dehydrogenase
(H6PDH) is a microsomal enzyme whose activity regulates corticosteroid metabolism in the liver and adipose tissue;
variability in measures of corticosteroid metabolism within the normal range have been associated with risk factors for
cardiovascular disease. We performed a genetic association study in 854 members of 224 families to assess the relationship
between polymorphisms in the gene coding for hexose-6 phosphate dehydrogenase (H6PD) and carotid intima-medial
thickness.
Methods: Families were ascertained via a hypertensive proband. CIMT was measured using B-mode ultrasound. Single
nucleotide polymorphisms (SNPs) tagging common variation in the H6PD gene were genotyped. Association was assessed
following adjustment for significant covariates including ‘‘classical’’ cardiovascular risk factors. Functional studies to
determine the effect of particular SNPs on H6PDH were performed.
Results: There was evidence of association between the single nucleotide polymorphism rs17368528 in exon five of the
H6PD gene, which encodes an amino-acid change from proline to leucine in the H6PDH protein, and mean carotid intima-
medial thickness (p = 0.00065). Genotype was associated with a 5% (or 0.04 mm) higher mean carotid intima-medial
thickness measurement per allele, and determined 2% of the population variability in the phenotype.
Conclusions: Our results suggest a novel role for the H6PD gene in atherosclerosis susceptibility.
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Introduction
Carotid artery intima-media wall thickness (CIMT), measured
by ultrasonography, is a subclinical marker of systemic athero-
sclerosis. There is a direct relationship between CIMT and the risk
of cardiovascular disease and stroke [1]. This association appears
to be independent of ‘‘traditional’’ risk factors such as hyperten-
sion and diabetes. Previous studies indicate that CIMT is a
significantly heritable phenotype [2].
Hexose-6 phosphate dehydrogenase (H6PDH) is a microsomal
enzyme which is a component of the pentose phosphate pathway.
It is thought to function in regenerating NADPH within the
endoplasmic reticulum for use in steroid hormone and drug
metabolism. H6PDH uses as substrate glucose-6 phosphate and
the cofactor NADP(+), producing 6-phosphogluconate and
NADPH. Although all molecular interactions of H6PDH are not
as yet known, its role in supplying NADPH to, and so regulating
the oxo-reductase activity of, 11-beta hydroxysteroid dehydroge-
nase type I (11b-HSD1), is well documented. NADPH generated
by H6PDH is an essential cofactor for the action of 11b-HSD1 in
reducing cortisone to cortisol, which takes place chiefly in the liver
and adipose tissue [3]. 11b-HSD1 oxo-reductase activity has been
implicated in the pathogenesis of several conditions related to
atherosclerosis, including diabetes and the metabolic syndrome
[4]. 11b-HSD1 inhibitors are an active area of pharmacological
research in view of their potential as anti-diabetic or anti-obesity
agents [5]. In view of its regulatory role on 11b-HSD1 activity, the
H6PD gene, which encodes the H6PDH protein, is a plausible
candidate gene for atherosclerosis susceptibility. No study to date,
however, has examined whether genetic variation in H6PD is
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associated with CIMT. We investigated this question in a large
family-based association study.
Methods
Population collection and phenotyping
Between 1993 and 1997, British Caucasian families were
ascertained from hypertensive probands for a quantitative genetic
study of cardiovascular risk factors. The local institutional review
committee approved the study, and all subjects gave written
informed consent. Two hundred and forty eight families with 1425
members were collected. The ascertainment strategy has been
described previously [6] [7] [8], and further details are presented
in Supporting Information S1. Between 1999 and 2001, families
were invited to attend for further phenotyping. 955 family
members (449 men and 506 women) out of a total of 1425
individuals who were invited attended. At this visit, carotid artery
ultrasonography was performed by two sonographers using a 7.5-
MHz linear array transducer (HP Sonos 5500). All measurements
were made by one trained physician (BMM). The scanning
protocol involved studying the right and left common carotid
arteries, measuring far-wall IMT according to a standard method
described by others [9] [10]. All scans were recorded on an optical
disc for later off-line analysis. End-diastolic frames (one from each
side of the body) were analysed for mean and maximal IMT, and
the average reading from these two frames was calculated. Scans
of sufficient quality were analysed with a previously described
computerised edge-detection system typically delivering interob-
server CVs of 2.5% [9]. As previously reported, intra-reader, inter-
reader and inter-sonographer reproducibility was assessed, and
found to be comparable to that achieved by other groups [2].
Ethics Statement
The project was approved by the Central Oxford, and by the
Newcastle and North Tyneside Research Ethics Committees, and
all subjects gave written informed consent.
TagSNP selection and genotyping
TagSNPs were selected from the phase 2 HapMap CEU data
from the region of the H6PD gene and 15 Kb upstream and
downstream (www.hapmap.org), using the Tagger utility of the
Haploview program and these parameters: minor allele frequency
.0.05; r2.0.8 [11]. 13 tagSNPs were required. A schematic view
of the H6PD gene and the SNPs typed is presented in Figure 1. All
TagSNPs were genotyped on a Sequenom MassArray MALDI-
TOF platform using iPLEX Gold chemistry. Primer sequences
and PCR conditions are presented in Supporting Information S1.
Control individuals of known genotype were included in every
plate, and 100 randomly selected samples were genotyped twice
for each polymorphism. Genotyping was carried out blinded to
phenotypic information. Mendelian inheritance of all the geno-
types, and Hardy-Weinberg equilibrium for each marker, were
checked using PEDSTATS [12]. Additional checks based on
unlikely recombination patterns within families were carried out
using the error-checking option in MERLIN [13]. Errors were
corrected when possible by reference to the raw genotyping data,
and when this was not possible genotypes were excluded from
analysis.
Statistical analysis
We examined the CIMT data for Normality; CIMT required
log-transformation to adequately conform to a Normal distribu-
tion. We examined for the presence of significant covariates, and
adjusted log-transformed CIMT for such covariates, using linear
regression. Age, age2, sex, alcohol consumption (in units per week),
smoking (graded current/former/never), exercise habit (graded
none versus some regular exercise), diabetes, and hypertension
affection status were considered as potential covariates of CIMT,
and included in the model if they achieved significance at p,0.05.
The log-transformed, covariate-adjusted residuals were then
entered into the quantitative trait genetic association analyses,
which were performed using a variance-components approach
which takes account of shared polygenic effects in members of the
same pedigree, implemented in the MERLIN package as
previously described [13]. To make some allowance for the testing
of multiple SNPs, we used the program QVALUE running on top
of the statistical package R to determine q-values [14]. The q-
value of a test measures the minimum false discovery rate that is
incurred when calling that particular test significant; the approach
taken by QVALUE involves using the vector of calculated p-values
for all individual tests as input. We adopted an arbitrary FDR
threshold of 0.05, that is, one in twenty of the associations passing
this criterion are expected to be false. Since there was a degree of
genotypic correlation due to LD between most of our tagSNPs
(though a tagSNP strategy selects against strong inter-SNP
correlation), this should be a conservative estimate.
Bioinformatic evaluation of H6PDH P554L variant
The evolutionary conservation of the 554 residue between
species was determined using Ensembl. The likely impact of the
P554L non-synonymous SNP in the H6PDH gene on H6PD
protein function was assessed using the PolyPhen prediction
program.
In vitro functional evaluation of H6PDH P554L variant
The in vitro effect of P554L on enzyme activity was assessed as
described previously [15]. In brief, wild-type (WT) and mutant
(P554L) H6PDH cDNA, contained in pcDNA3.1D/V5-His-
TOPO (Invitrogen, Paisley, UK), were used to transfect a human
embryonic kidney cell line (HEK 293), devoid of endogenous
H6PDH. Three stably transfected cell lines were derived from
three separate transfection experiments for WT and P554L, with
cells mock transfected with empty vector used as a further control.
Successful and equal transfection levels were confirmed using
H6PDH-specific, quantitative PCR using commercially available
assays (Target sequence NM_004285.3; Applied Biosystems
Taqman Probe ID: Hs00188728_m1) used according to the
manufacturer’s instructions. H6PDH assays were performed on
WT and mutant microsomes prepared from HEK 293 cells
(ATCC, Manassas, USA) by spectrofluorometric detection of
NADPH generation. Microsomes were permeabilized with 0.5%
Triton X-100 and incubated in 50 mM glycine buffer (pH 9.0) at
37 C in the presence of 1 mM G6P and 0.4 mM NADP+.
Absorbance readings were recorded using a luminescence
spectrometer (excitation 340 nm, emission 456 nm), and readings
converted to nmoles NADPH produced/min/mg of total
microsomal protein.
Results
Demographics and phenotype distribution
There were 854 members of 224 families who had acceptable
CIMT measurements. Demographics and phenotype distribution
of these participants are shown in Table 1 (and the corresponding
information for the entire population is presented in Supporting
Information S1). As expected given the ascertainment on a
hypertensive proband, participants had on average higher systolic
and diastolic blood pressures than a general population. We used
H6PD Polymorphisms and CIMT
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mean CIMT as the principal variable after preliminary analyses
showed highly similar results for mean and maximal CIMT
phenotypes, which were strongly correlated (r = 0.98). The
distribution of the mean CIMT values lay mainly within the
normal population range (median observed 0.76 mm, IQR 0.64–
0.91 mm; normal range 0.4–1.0 mm). The distribution of the
mean CIMT data was significantly skewed, and was therefore
transformed by taking the natural logarithm, after which the
distribution conformed to Normality. The significant covariates for
loge mean CIMT were age, age-squared, sex, alcohol consumption
(in women only) and physical exercise. These covariates were all
highly significant (p,0.005), and accounted for 38.9% of
variability in loge mean CIMT. Following adjustment for
covariates, the heritability of loge mean CIMT was 22%
(p,0.001).
Analysis of association between H6PD SNPs and CIMT
Genotyping was successful in over 97% of samples for all SNPs.
There was no significant deviation from Hardy-Weinberg
proportions for any SNP (all p.0.05). Minor allele frequencies
of the typed SNPs varied from 0.09 to 0.49, and were in close
correspondence with the HapMap data (CEU population) for all
SNPs. As expected given the tagSNP selection strategy, correlation
(r2) between SNPs was generally modest (Supporting Information
S1). The estimated genotyping error rate was less than 1%. The
rs17368528 SNP in exon 5 of H6PD was significantly associated
with adjusted log [mean CIMT] (p-value for linear
trend= 0.00065; Table 2), with carriers of the minor T allele
having higher mean CIMT. However, the number of homozy-
gotes for the T allele was small. Therefore, to rule out a
disproportionate influence from rare outliers on the result a test
Figure 1. The H6PD gene, showing SNPs typed in this study. SNPs are shown in the context of Haploview output showing all SNPs typed in
the CEU population of the HapMap project. Exons are represented as blue boxes. In the Haploview triangle plot D9 is represented, and stronger LD is
indicated by red filled squares.
doi:10.1371/journal.pone.0023248.g001
H6PD Polymorphisms and CIMT
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comparing T allele carriers with non-carriers was also performed
(that is, a dominant model); this was similarly significant
(p = 0.007, Table 2). Genotype explained 2% of the variability in
adjusted log [mean CIMT], or around 9% of the genetic
variability in the phenotype. Simple exponentiation indicates each
T allele increases mean CIMT by approximately 5%, which in our
population would translate to around 0.04 mm. As expected, some
of the other tagSNPs that were in LD with rs17368528 had weaker
evidence of association with CIMT, but only rs17368528
remained significant at an FDR threshold of 0.05 using QVALUE.
A boxplot showing the relationship between CIMT and
rs17368528 genotype is presented in Figure 2.
As the cohort was selected for blood pressure, it was particularly
important to rule out any confounding effect of blood pressure on
our results. While this would largely have been accomplished by
our principal approach, which involved adjusting CIMT for any
effect of blood pressure, we also carried out subsidiary analyses to
test whether there was any effect of H6PD genotypes on blood
pressure. No significant association of genotype with blood
pressure, considered either quantitatively or qualitatively, was
observed at any SNP typed.
Bioinformatic analysis of P554L variant
The rare allele of the rs17368528 SNP results in a substitution
of leucine for proline at position 554 of the H6PD protein
(Pro554Leu). Bioinformatic analysis of this substitution using the
prediction tool PolyPhen indicated it to be ‘‘probably damaging’’.
In addition, alignments of known H6PDH protein sequences
revealed proline 554 to be highly conserved and therefore likely to
be of functional importance (Figure 3A).
In vitro functional analysis of P554L variant
The standard H6PD activity assay we performed did not detect
any significant differences in enzyme function between WT and
P554L variants with respect to their capacity to generate NADPH
(Figure 3B).
Discussion
We describe genetic association between a nonsynonymous
SNP in exon 5 of H6PD and carotid intima-medial thickness. The
association accounts for just under 2% of the total population
variability, which represents just under 10% of the heritability of
the phenotype in our cohort. CIMT was 5% higher per copy of
the rare T allele at rs17368528. The rs17368528 SNP encodes a
proline to leucine substitution in exon 5 of H6PD and is predicted
to have a deleterious effect on protein function.
Although there have been many previous candidate gene
association studies of CIMT (for example, over 100 are recorded
in the Genetic Association Database; www.geneticassociationdb.
nih.gov) none so far has, to our knowledge, investigated the H6PD
gene. A systematic review of all published candidate gene studies
of CIMT up to 2010 suggested modest association with the
Apolipoprotein E epsilon2/epsilon3/epsilon4 isoform polymor-
Table 1. Characteristics of the Population.
Variable n Minimum Lower Quartile *Median/Percentage Upper Quartile Maximum {R2
Age (years) 854 18.7 37.7 51.0 59.9 88.1 -
Gender(female) 854 52.1 -
Hypertensive 802 41.5 -
Diabetes 438 2.1 -
Smoker 852 19.2 -
Take No Exercise 846 40.0 -
Alcohol Consumption
(units per week)
852 0 0 3.5 12.0 80.0 -
Clinic Systolic Blood
Pressure (mmHg)
738 86.0 122.3 135.0 154.0 226 28.8
Clinic Diastolic Blood
Pressure (mmHg)
737 47.0 74.0 83.0 93.0 135.7 16.7
BMI (kg/m2) 846 17.2 23.3 25.5 28.3 51.8 14.9
WHR 835 0.63 0.78 0.85 0.91 1.20 49.6
Total Cholesterol (mMol/l) 777 2.6 4.8 5.5 6.3 10.6 18.0
IMT mean (mm) 854 0.42 0.65 0.76 0.91 2.17 38.9
{Proportion of variability explained by correction for covariates. All variables were log-transformed before correction, except WHR, to achieve approximate Normality.
*Medians are given for continuous variables and percentages for binary variables.
doi:10.1371/journal.pone.0023248.t001
Table 2. Association of CIMT with rs17368528 genotype.
Mean (standard error, n) for each genotype at rs17368528
p-values for linear trend, and for CT+TT v
CC
Variable CC CT TT
Adjusted log IMT mean 20.0101(0.008, 616) 0.0402(0.018, 149) 0.1080(0.145, 2) 0.00065, 0.007
doi:10.1371/journal.pone.0023248.t002
H6PD Polymorphisms and CIMT
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phism only; this did not appear to be confounded by publication
bias in favour of small positive studies. By contrast, review of the
published literature for other commonly studied polymorphisms
including the insertion/deletion polymorphism of the angiotensin-
1 converting enzyme gene (ACE I/D), and the C677T SNP in the
5,10-methylenetetrahydrofolate reductase gene (MTHFR),
showed evidence of publication bias likely to be of equal or
greater magnitude than any true genetic effect [16].
Published data from association studies typing many thousands
of SNPs that have included CIMT as a phenotype at present
remain at low resolution and of comparable size to the present
study. The Framingham Heart Study investigators obtained
genotypes at 100,000 SNPs genomewide on around 970
individuals and observed evidence of association that approached
genomewide significance levels at rs1376877 on chromosome 2q
and rs4814615 on chromosome 20p. No significant association
was reported in the region of H6PD, but rs17368528 was not
represented on the chip used in that study [17]. Recently Lanktree
and colleagues presented a multi-ethnic genetic association study
of CIMT in a total of 898 people using a targeted, collaboratively
designed, gene-centric 50,000 SNP chip covering some 2100
candidate genes for atherosclerotic cardiovascular disease, which
demonstrated significant association with SNPs in the histone
deacetylase 4 (HDAC4) and natriuretic peptide receptor A (NPR1)
genes [18]. Many other genetic epidemiological cohort studies,
Figure 3. Bioinformatic and functional investigation of rs17368528. A) H6PDH protein sequence alignments indicating the strict
conservation of Proline 554 (red box) between species. B) H6PDH activity assays performed on microsomal preparations from HEK-293 cells
transfected with empty vector (Mock), and WT and P554L expression constructs. There was no significant difference in activity between WT and
P554L.
doi:10.1371/journal.pone.0023248.g003
Figure 2. Boxplot of mean CIMT by rs17368528 genotype.
doi:10.1371/journal.pone.0023248.g002
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including some with CIMT data, are presently genotyping this
same chip and may replicate those findings, however, the chip
does not include SNPs in H6PD [19]. Replication of our result by
others will therefore await the result of genotyping large cohorts in
which CIMT has been measured using denser SNP panels or of
focused genotyping in the H6PD region.
We calculated that the increase in CIMT associated with
homozygosity for the T allele at rs17368528 compared with
homozygosity for the C allele is around 0.1 mm. Taken together,
previous prospective studies suggest that differences of this order in
IMT measured at baseline would be associated with an increase in
relative risk for myocardial infarction and stroke over time of only
around 1.10 [10] [20]. Association between H6PD genotypes and
clinical endpoints of stroke or myocardial infarction have not been
observed in large-scale genome-wide association studies of those
endpoints conducted so far. However, studies published to date do
not have adequate power to rule out effects on endpoints of the
size that would be anticipated given the association we describe
with the quantitative phenotype. Given the size of the effect we
have detected, it seems unlikely that rs17368528 genotype would
be useful in individualized risk stratification; however, our finding
does point to a hitherto unrecognized potential role of H6PDH in
atherosclerosis susceptibility.
Inhibition of H6PDH activity, and thus depletion of the ER
luminal store of NADPH, sensitizes cells to oxidative stress and
thus promotes apoptosis, which is a key process in the vessel wall in
the initiation and progression of atherosclerosis [21]. Although
PolyPhen analysis and sequence alignments suggested the
Pro554Leu variant to be ‘‘probably damaging’’, in vitro functional
assays did not reveal any significant, large scale effects of this
mutation on NADPH generation compared to WT H6PDH.
There are however, certain caveats to the functional assay used in
this study. Firstly, the method would not be able to detect subtle
differences (decreases or increases) in the kinetic parameters that
might arise due to this mutation, since the assay uses only crude
cell extracts and measures only initial rates, with saturating
substrate concentrations. Secondly, H6PDH is a bifunctional
enzyme with both glucose-6-phosphate dehydrogenase activity
(which is responsible for the NADPH generation) and 6-
phosphogluconolactonase activity [22]. The P554L mutation is
situated at the junction between the enzyme domains responsible
for these two functions. The assay carried out in this study only
directly measured NADPH generation (glucose-6-phosphate
dehydrogenase activity) and not 6-phosphogluconolactonase
activity, which is much more difficult to assay. 6-phosphogluco-
nolactonase activity accelerates the hydrolysis of the reactive/toxic
intermediate 6-phosphogluconolactone [23]. Any interference
with the functionality of the second domain could also affect the
generation of NADPH by the first domain. In order to carry out
further analyses of the effect of the mutation on 6-phosphogluco-
nolactonase activity, further experiments using highly purified
protein will be required. Finally, H6PDH and 11b-HSD1 have
been reported to have a direct protein-protein interaction which
facilitates the reductive activity of 11b-HSD1 [24] and this could
not be assessed in our assay. The precise residues involved in the
interaction between the two proteins have not been fully
elucidated, but it is possible that the P554L mutation may affect
this interface 23. Further experiments will therefore be required to
identify the specific mechanism whereby H6PD Pro554Leu affects
atherosclerosis susceptibility.
Our result was obtained in a large study of families closely
characterized for many potential confounders, for which it was
possible to carry out adjustment before the genetic analyses. It is
robust to a correction for multiple comparisons in which we
adopted an FDR of 1 in 20. However, as with any hypothesis-
originating study, replication in an independently ascertained
cohort will be important in due course. Given the modest absolute
size of the effect (0.1 mm difference between genotypes) and the
technical demands of accurately measuring CIMT on large
numbers of participants, this might be challenging. Pharmacolog-
ical inhibitors of 11b-HSD1 are presently the focus of a great deal
of interest because of their possible role in decreasing the risk of
obesity and the metabolic syndrome. Our result suggests that more
detailed investigations of the role of the endoplasmic reticulum
redox system in atherosclerosis is warranted to fully understand the
potential implications of such agents and design potential new
compounds.
Conclusions: Study Relevance
Pre-receptor regulation of glucocorticoid signaling is implicated
in the development of obesity and the metabolic syndrome. Drugs
to modulate the activity of this system are presently in clinical
evaluation. Our result suggests that in addition to effects on the
metabolic syndrome, this pathway has direct effects on the
atherosclerotic process that may be of therapeutic importance.
Supporting Information
Supporting Information S1 Supporting Information S1 con-
tains Supplementary Methods, Supplementary Tables 1, 2, and 3,
and Supplementary Figure 1.
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